Long-Acting Opioid REMS Tally: FDA Lists 12 Brand, 23 Generic
Nineteen companies will implement individual Risk Evaluation and Mitigation Strategies for long-acting/extended-release opioid products that are subject to the class-wide REMS unveiled by FDA July 9.
You may also be interested in...
Depomed is leveraging all its value to bet on a drug that was virtually ignored by its big pharma owner with its billion-dollar buy of Janssen’s Nucynta.
Endo files suit against FDA seeking preliminary injunction to require FDA to say whether Endo’s withdrawal of non-crush resistant Opana ER was for safety reasons; FDA contends it has until May 10, 2013 to make this decision.
But Purdue and Teva disagree on the key question of whether a generic of a tamper-resistant analgesic must have the same dosage form as the reference-listed brand-name drug.